CBD FOR INDIVIDUALS AT RISK FOR ALZHEIMER'S DISEASE

Research study recruiting participants who want to use cannabidiol (CBD) for mild cognitive impairment.

Main procedures include questionnaires, blood draws, health review, drug and pregnancy tests, and cognitive tests.

INCLUSION CRITERIA
- Between 55 - 85 years old
- Diagnosis of mild cognitive impairment
- Can independently provide valid informed consent and has a knowledgeable informant regarding their condition

DURATION OF PARTICIPATION
Participation will last approximately 26 weeks. CBD or placebo will be used for 24-weeks.

CONTACT INFORMATION
(720) 651-8222 | mci.study@cuanschutz.edu

COMPENSATION AND STUDY MEDICATION PROVIDED